LIAISON® BRAHMS MR-proADMTM
A powerful solution for Emergency Department (ED) decision-making.
Accurate prioritization of critically ill patients with suspected infection for timely and informed decision-making when every second counts.
Tell us who you are
Background
Empower your lab with a new solution to support ED and ICU physicians in improving patient care
The role of the clinical laboratory in supporting clinical decision-making is crucial. Empower your laboratory with the new MR-proADMTM biomarker, to assess disease severity and potential disease progression in patients presenting to the emergency department (ED) with a suspected acute infection.
LIAISON® BRAHMS MR-proADMTM is a high-quality quantitative CLIA assay that measures the concentration of the blood biomarker Mid-regional pro-adrenomedullin (MR-proADMTM) to assess disease severity and prognosis in patients with a suspected infection.
Incorporation into the laboratory routine may therefore aid rapid clinical decision-making to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment.
How it works
LIAISON® BRAHMS MR-proADMTM automatically quantifies the circulating MR-proADMTM in a plasma sample, to evaluate the severity of endothelial dysfunction and the risk of organ failure and/or sepsis development in several clinical conditions: sepsis and septic shock, urinary tract infections (UTI); lower respiratory tract infections (LRTI) and kidney diseases.
Accurately detects patients at risk in the ED and ICU
No need for specialized staff
The fully automated LIAISON® BRAHMS MR-proADMTM test is part of Diasorin’s comprehensive portfolio of immunoassays, allowing any laboratory to optimize its diagnostic pathway while meeting critical emergency department timelines.
35 minutes to results
Fast results give clinicians swift answers in emergency situations.
High-quality, ready-to-use CLIA assay
Standardized and unbiased results with automatic processing ensures optimal harmonization between urgent, specialty and routine tests
Why use LIAISON® BRAHMS MR-proADMTM
Quick, objective diagnostics to improve your precision and responsiveness.
Pioneering, easy-to-use diagnostic solution
The easy, intuitive process ensures perfect harmonization between urgent, specialty and routine tests.
Meet critical emergency department timelines
Optimize your diagnostic pathway and deliver faster time-to-results without the need for additional staff.
Better performance for an innovative biomarker
MR-proADMTM offers an accurate and reliable evaluation of endothelial and microcirculatory damage to rapidly identify the risk of organ damage.
Empower your lab
Dynamic throughput with fully automated processing improves response time without increasing operational costs.
To be used on
Designed for both specialty and routine tests, LIAISON® XL and LIAISON® XS immunoassay analyzers help your laboratory handle multiple patients and tests simultaneously. LIAISON® systems are trustworthy, intuitive and deliver automated continuous operation with minimal user intervention. The result is reduced turnaround time, optimal cost management and unmatched growth potential.
LIAISON® XL
Designed for large laboratories. Fuse the benefits of high throughput and high sensitivity within a powerful and fully automated system that can seamlessly connect to facilitate Total Laboratory Automation.
LIAISON® XS
A fully automated, easy-to-use benchtop analyzer. Maximize productivity with optimal cost management, no daily maintenance, straightforward integration, and the same capabilities as Diasorin’s high-throughput analyzers.
More details about our diagnostic solutions
Login to Dialog for additional resources
Login to our repository for instructions for use and user manuals, assay information, protocols and much more.
Background
Safely identify severely ill patients to improve ED risk stratification and triage level determination
There is a lack of validated tools (blood biomarkers and clinical scores) to timely assess potential disease progression and hospitalization decisions in patients presenting to the emergency department (ED) with a suspected acute infection.
LIAISON® BRAHMS MR-proADM™ is a high-quality quantitative CLIA assay that measures the concentration of the blood biomarker Mid-regional pro-adrenomedullin (MR-proADM™) to assess disease severity and prognosis in patients with a suspected infection.
Incorporation into an early sepsis management protocol at ED triage, may therefore aid the rapid decision-making to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment.
How it works
LIAISON® BRAHMS MR-proADM™ automatically quantifies the circulating MR-proADM™ in a plasma sample, to evaluate the severity of endothelial dysfunction and the risk of organ failure and/or sepsis development in several clinical conditions: sepsis and septic shock, urinary tract infections (UTI); lower respiratory tract infections (LRTI) and kidney diseases.
Accurately detects patients at risk in the ED and ICU
35 minutes to results
Aid timely clinical decision making (rule in/rule out hospitalization) using LIAISON® analyzers.
Optimized patient disposition at ED
Identify early signs of sepsis and organ failure in patients with an infection – regardless of its etiology: bacterial, viral or fungal.
Easy-to-interpret results
Explicit cut-off values indicate whether to hospitalize or safely discharge the patient.
Why use LIAISON® BRAHMS MR-proADMTM
Streamlines the clinical pathway.
Early diagnosis of sepsis
Early identification of high-risk patients, reduction of adverse events, improved prognosis at ED.
Improved bed management at ED
Better ED patient flow and more time and space for trauma and patients in need of ED resources.
Cost savings
Better overall utilization of hospital resources (e.g., less labor, fewer admissions and additional tests required).
Increased patient satisfaction
Optimized diagnostic pathway improves the quality of healthcare.
To be used on
Designed for both specialty and routine tests, LIAISON® XL and LIAISON® XS immunoassay analyzers help your laboratory handle multiple patients and tests simultaneously. LIAISON® systems are trustworthy, intuitive and deliver automated continuous operation with minimal user intervention. The result is reduced turnaround time, optimal cost management and unmatched growth potential.
LIAISON® XL
Designed for large laboratories. Fuse the benefits of high throughput and high sensitivity within a powerful and fully automated system that can seamlessly connect to facilitate Total Laboratory Automation.
LIAISON® XS
A fully automated, easy-to-use benchtop analyzer. Maximize productivity with optimal cost management, no daily maintenance, straightforward integration, and the same capabilities as Diasorin’s high-throughput analyzers.
More details about our diagnostic solutions
Login to Dialog for additional resources
Login to our repository for instructions for use and user manuals, assay information, protocols and much more.